Albendazole-cyclodextrin complex: Enhanced cytotoxicity in ovarian cancer cells

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2775-2779

  Pourgholami, Mohammad H ^a,b   Wangoo, Kiran T ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Cyclodextrin; Albendazole; Efficacy; Ovarian cancer; Toxicity

Indexed keywords

ALBENDAZOLE; BETA CYCLODEXTRIN; CITRIC ACID;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER TUMOR; OVARY CANCER; PRIORITY JOURNAL;

ALBENDAZOLE; BETA-CYCLODEXTRINS; BIOCOMPATIBLE MATERIALS; CELL LINE, TUMOR; FEMALE; HEPATOCYTES; HUMANS; OVARIAN NEOPLASMS; SOLUBILITY;

EID: 55749113885     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pourgholami MH, Akhter J, Wang L, Lu Y and Morris DL: Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55: 425-432, 2005.
2. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P and Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 165: 43-49, 2001.
3. Morris DL, Jourdan JL and Pourgholami MH: Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. Oncology 61: 42-46, 2001.
4. Pourgholami MH, Yan Cai Z, Lu Y, Wang L and Morris DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12: 1928-1935, 2006.
5. Khalilzadeh A, Wangoo KT, Morris DL and Pourgholami MH: Epothilone-paclitaxel-resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol 74: 407-414, 2007.
6. Jung H, Medina L, Garcia L, Fuentes I and Moreno-Esparza R: Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol 50: 43-48, 1998.
7. Gottschall DW, Theodorides VJ and Wang R: The metabolism of benzimidazole anthelmintics. Parasitol Today 6: 115-124, 1990.
8. Uekama K and Otagiri M: Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst 3: 1-40, 1987.
9. Piel G, Evrard B, Van Hees, T, Llabres G and Delattre L: Development of a parenteral and of an oral formulation of albendazole with cyclodextrins. STP Pharma Sci 9: 257-260, 1999.
10. Loftsson T, Vogensen SB, Brewster ME and Konradsdottir F: Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 96: 2532-2546, 2007.
11. Cai ZY, Galettis P, Lu Y, Morris DL and Pourgholami MH: Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. Anticancer Res 27: 417-422, 2007.
12. Papazisis KT, Geromichalos GD, Dimitriadis KA and Kortsaris AH: Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208: 151-158, 1997.
13. Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J and Martin SG: Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer 92: 350-358, 2005.
14. Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977.
15. Haghighi KS, Woon WW, Akhter J, Marr PJ, Bolton E, Riordan Sand Morris DL: A new source of hepatocytes for transplantation. Transplant Proc 36: 2466-2468, 2004.
16. Ferrara Nand Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005.
17. Brewster ME, Estes KS and Bodor N: An intravenous toxicity study of 2-hydroxypropyl-[beta]-cyclodextrin, a useful drug solubilizer, in rats and monkeys. Int J Pharm 59: 231-243, 1990.
18. Fahr A and Liu X: Drug delivery strategies for poorly watersoluble drugs. Expert Opin Drug Deliv 4: 403-416, 2007.
19. Ohtani Y, Irie T, Uekama K, Fukunaga K and Pitha J: Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur J Biochem 186: 17-22, 1989.
20. Legendre JY, Rault I, Petit A, Luijten W, Dmuynck I, Horvath S, Ginot YM and Cuine A: A Effect of β-cyclodextrin on skin-implication for the transdermal delivery of pinbedil and a novel cognition enhancing drug. Eur J Pharm Sci 3: 311-322, 1995
21. Loftsson T, Sigurdardottir AM and Olafsson JH: Improved acitretin delivery through hairless mouse skin by cyclodextrin complexation. Int J Pharm 115: 255-258, 1995.
22. Vollmer U, Muller BW, Peelers J, Mesens J, Wilffert B and Peters T: A study of the percutaneous absorption-enhancing effects of cyclodextrin derivatives in rats. J Pharm Pharmacol 46: 19-22, 1994.
23. Bentley MV, Vianna RF, Wilson S and Collect JH: Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J Pharm Pharmacol 49: 397-402, 1997.
24. Evrard B, Chiap P, DeTullio P, Ghalmi F, Piel G, Van Hees T, Crommen J, Losson B and Delattre L: Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin. J Control Release 85: 45-50, 2002.
25. Fernanda O, Paias VLL, Osvaldo M, Takayanagui P and Sueli Bonato: Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis. Electrophoresis 22: 3263-3269, 2001.
26. Diaz D, Bernad MJ, Gracia MJ and Escobar CM: Complexation and solubility behavior of albendazole with some cyclodextrins. Pharm Dev Technol 3: 395-403, 1998.
27. Uekama K, Narisawa S, Hirayama F and Otagiri M: Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation. Int J Pharm 16: 327, 1983.
28. Puglisi G, Sanatagati NA, Pignatello R, Ventura C and Mazzone G: Inclusion complexation of 4-biphenylacetic acid with β-CD. Drug Dev Ind Pharm 16: 395-413, 1990.
29. Pitha J, Irie T, Sklar PB and Nye JS: Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci 43: 493-502, 1988.